2005 Fiscal Year Final Research Report Summary

Delivery of genomic protein drug using the chemical modification with basic peptide and biodegradable minicapsules

Research Project

Project/Area Number	16590128
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Single-year Grants
Section	一般
Research Field	Medical pharmacy
Research Institution	Kyoto Pharmaceutical University
Principal Investigator	YAMAMOTO Akira Kyoto Pharmaceutical University, Department of Biopharmaceutics, Professor, 薬学部, 教授 (00166779)
Project Period (FY)	2004 – 2005
Keywords	Basic peptide / Cell penetrating peptide / Chitosan capsules / Biodegradable / Protein drug / Genomic drug / Transmucosal absorption / Absorption enhancement
Research Abstract	The objective of this study was to estimate the colon-specific delivery of [Asu^<1,7>]-eel calcitonin (ECT) using chitosan capsules in rats. The intestinal absorption of ECT was evaluated by measuring the plasma calcium levels after oral administration of the chitosan capsules containing ECT and different combinations of additives. A marked decrease in plasma calcium levels was observed following the oral administration of chitosan capsules containing ECT, S-nitroso-N-acetyl-DL-penicillamine (SNAP), sodium glycocholate, bacitracin and aprotinin, as compared with capsules containing only ECT or capsules containing ECT with SNAP only. The hypocalcemic effect started 6-8 hr after oral administration of capsules and sustained for 24 hr. These findings suggest that colon-specific delivery of ECT can be achieved using chitosan capsules and these additives may be useful for improving the colonic absorption of ECT in rats.

(3 results)